Correcting anemia and native vitamin D supplementation in kidney transplant recipients: a multicenter, 2 × 2 factorial, open-label, randomized clinical trial.

allograft function anemia cancer erythropoiesis-stimulating agents kidney transplant malignancy vitamin D

Journal

Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516

Informations de publication

Date de publication:
07 2021
Historique:
revised: 10 03 2021
received: 11 11 2020
accepted: 03 04 2021
pubmed: 23 4 2021
medline: 3 8 2021
entrez: 22 4 2021
Statut: ppublish

Résumé

Anemia and vitamin D deficiency are associated with allograft failure, and hence, are potential therapeutic targets among kidney transplant recipients (KTRs). We conducted a multicenter, two-by-two factorial, open-label, randomized clinical trial to examine the effects of anemia correction and vitamin D supplementation on 2-year change in eGFR among KTRs (CANDLE-KIT). We enrolled 153 patients with anemia and >1-year history of transplantation across 23 facilities in Japan, and randomly assigned them to either a high or low hemoglobin target (>12.5 vs. <10.5 g/dl) and to either cholecalciferol 1000 IU/day or control. This trial was terminated early based on the planned interim intention-to-treat analyses (α = 0.034). Among 125 patients who completed the study, 2-year decline in eGFR was smaller in the high vs. low hemoglobin group (i.e., -1.6 ± 4.5 vs. -4.0 ± 6.9 ml/min/1.73 m

Identifiants

pubmed: 33884674
doi: 10.1111/tri.13885
doi:

Substances chimiques

Vitamin D 1406-16-2

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1212-1225

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 24890109
Organisme : The Kidney Foundation, Japan
ID : JKFB 13-13

Investigateurs

Yoshitsugu Obi (Y)

Informations de copyright

© 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd.

Références

Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56: 783.
Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167.
Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004; 4: 1562.
Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006; 69: 560.
Ichimaru N, Obi Y, Nakazawa S, et al. Post-transplant anemia has strong influences on renal and patient outcomes in living kidney transplant patients. Transplant Proc 2016; 48: 878.
Heinze G, Kainz A, Horl WH, Oberbauer R. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 2009; 339: b4018.
Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266.
Nakano C, Hamano T, Fujii N, et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 2012; 7: 810.
Hamano T, Nakano C, Obi Y, et al. Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. Kidney Int Suppl 2011; 2013: 469.
Obi Y, Hamano T, Wada A, Tsubakihara Y, Committee of Renal Data Registry of the Japanese Society for Dialysis T. Vitamin D receptor activator use and cause-specific death among dialysis patients: a nationwide cohort study using coarsened exact matching. Sci Rep 2017; 7: 41170.
Obi Y, Hamano T, Isaka Y. Prevalence and prognostic implications of vitamin D deficiency in chronic kidney disease. Dis Markers 2015; 2015: 868961.
Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 2010; 29: 86.
Singh AK, Szczech L, Tang KL, et al. Correction of anemia with Epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085.
Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071.
Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019.
Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532.
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012; 2: 279.
Choukroun G, Kamar N, Dussol B, et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 2012; 23: 360.
Bienaimé F, Girard D, Anglicheau D, et al. Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol 2013; 24: 831.
Obi Y, Hamano T, Ichimaru N, et al. Vitamin D deficiency predicts decline in kidney allograft function: a prospective cohort study. J Clin Endocrinol Metab 2014; 99: 527.
Obi Y, Ichimaru N, Hamano T, et al. Orally active vitamin D for potential chemoprevention of posttransplant malignancy. Cancer Prev Res (Phila) 2012; 5: 1229.
Ducloux D, Courivaud C, Bamoulid J, Kazory A, Dumoulin G, Chalopin JM. Pretransplant serum vitamin D levels and risk of cancer after renal transplantation. Transplantation 2008; 85: 1755.
Sarno G, Nappi R, Altieri B, et al. Current evidence on vitamin D deficiency and kidney transplant: what's new? Rev Endocr Metab Disord 2017; 18: 323.
Ban TH, Kim JH, Jang HB, et al. Clinical effects of pre-transplant serum 25-hydroxyvitamin D level on post-transplant immunologic and non-immunologic outcomes in kidney transplant recipients. Transpl Immunol 2017; 40: 51.
McGregor R, Li G, Penny H, Lombardi G, Afzali B, Goldsmith DJ. Vitamin D in renal transplantation - from biological mechanisms to clinical benefits. Am J Transplant 2014; 14: 1259.
Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982.
Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis 2013; 61: 197.
CANDLE-KIT Trial Study Group, Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients (CANDLE-KIT) ClinicalTrials.gov: NIH U.S. National Library of Medicine; [updated February 4, 2019. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01817699.
Gallagher JC, Sai A, Templin T 2nd, Smith L. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med 2012; 156: 425.
Lan K, DeMets D. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659. Mathematical Reviews (MathSciNet): MR725380 Zentralblatt MATH. 1983;543.
Tsujita M, Kosugi T, Goto N, et al. The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. Nephrol Dial Transplant 2019; 34: 1409.
Agarwal R, Hynson JE, Hecht TJ, Light RP, Sinha AD. Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. Kidney Int 2011; 80: 1073.
Kusunoki Y, Matsui I, Hamano T, et al. Excess 25-hydroxyvitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype. Kidney Int 2015; 88: 1013.
Thiem U, Kaider A, Schwantzer-Gssler U, eds., et al. VITA-D study: outcome of a 1-year randomized controlled trial to evaluate vitamin D3 supplementation in vitamin D deficient renal transplant patients. European Renal Association- European Dialysis and Transplant Association (ERA-EDTA) 52nd Congress; 2015 28-31 May, 2015. London, UK.
Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 2017; 69: 815.

Auteurs

Yoshitsugu Obi (Y)

Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
Obi Clinic, Osaka, Japan.
Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN, USA.

Naotsugu Ichimaru (N)

Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Suita, Japan.

Yusuke Sakaguchi (Y)

Department of Inter-Organ Communication Research in Kidney Disease, Osaka University Graduate School of Medicine, Suita, Japan.

Kazuhiro Iwadoh (K)

Department of Surgery III, Tokyo Women's Medical University, Tokyo, Japan.
Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan.

Daisuke Ishii (D)

Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan.

Ken Sakai (K)

Department of Nephrology, Omori Medical Center, Toho University School of Medicine, Tokyo, Japan.

Daiki Iwami (D)

Department of Urology, Hokkaido University, Sapporo, Japan.
Division of Renal Surgery and Transplantation, Department of Urology, Jichi Medical University, Shimotsuke, Japan.

Hiroshi Harada (H)

Department of Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan.

Keiichi Sumida (K)

Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN, USA.
Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, Japan.

Akinari Sekine (A)

Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, Japan.

Kosuke Masutani (K)

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Naotake Akutsu (N)

Department of Surgery and Clinical Research Center, Chibahigashi National Hospital, National Hospital Organization, Chiba, Japan.

Takamitsu Inoue (T)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

Morikuni Nishihira (M)

Department of Nephrology, Tomishiro Central Hospital, Tomigusuku, Japan.

Tatsuo Yoneda (T)

Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.

Shinichi Ito (S)

Sunshine M&D Clinic, Mizuho, Gifu, Japan.

Motoo Araki (M)

Department of Urology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

Jun-Ya Kaimori (JY)

Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Inter-Organ Communication Research in Kidney Disease, Osaka University Graduate School of Medicine, Suita, Japan.

Katsunori Yoshida (K)

Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.

Shigeru Satoh (S)

Center for Kidney Disease and Transplantation, Akita University Hospital, Akita, Japan.

Yoshifumi Ubara (Y)

Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, Japan.

Yoshitaka Isaka (Y)

Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.

Kazunari Yoshida (K)

Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan.
Research and Development Center for New Medical Frontiers, Organ Transplant Medicine, Kitasato University School of Medicine, Sagamihara, Japan.

Yoshiharu Tsubakihara (Y)

Department of Safety Management in Health Care Sciences, Graduate School of Health Care Sciences, Jikei Institute, Osaka, Japan.

Shiro Takahara (S)

Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Renal Transplantation, Kansai Medical Hospital, Toyonaka, Japan.

Takayuki Hamano (T)

Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Inter-Organ Communication Research in Kidney Disease, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Nephrology, Graduate School of Medical Science, Nagoya City University, Nagoya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH